Data compiled by Redley Lamar · ChainSifter Intelligence
5Suppliers
4Customers
2Debt Items
1Related Chains
Source-Backed Evidence Depth
Traws Pharma, Inc. (TRAW) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
12Total relationships
3Distinct source URLs
9High confidence
0.837Average confidence
2026-07-01Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Traws Pharma, Inc. Suppliers
Ticker
Name
Confidence
Evidence
CHEMDIV
CHEMDIV
92%
Pursuant to the Master Research and Development Agreement, ChemDiv provided services related to preclinical drug discovery to Trawsfynydd prior to the acquisition and continues to provide services to…
CHEMDIV-INC
CHEMDIV-INC
92%
Pursuant to the Master Research and Development Agreement, ChemDiv provided services related to preclinical drug discovery to Trawsfynydd prior to the Merger and continues to provide services to the …
VIRIOM
VIRIOM
92%
During the period from January 1, 2025 through December 2025 and the year ended December 31, 2024, the Company incurred R&D expense of $244,000 and $128,000, respectively, in the Company’s consolidat…
EXPERT
EXPERT
90%
Pursuant to the Master Research and Development Agreement, Expert provided drug development and consulting services to Trawsfynydd prior to the acquisition and continued to provide services to the Company.
TEMPLE-UNIVERSITY
TEMPLE-UNIVERSITY
90%
Under one of these agreements with Temple University, the Company is required to make annual maintenance payments to Temple and royalty payments based upon a percentage of sales generated from any pr…
Traws Pharma, Inc. Customers
Ticker
Name
Confidence
Evidence
KNIGHT
KNIGHT
92%
we have agreed to supply Knight with all of its requirements of the Knight Licensed Products
ONCONOVA-THERAPEUTICS-INC
ONCONOVA-THERAPEUTICS-INC
62%
k issued in connection with the reclassification and conversion of redeemable convertible preferred stock $ — $ 111,619,000 Common stock issued in connection with acquisition of Trawsfynydd $…
SYMBIO-PHARMACEUTICALS-LIMITED
SYMBIO-PHARMACEUTICALS-LIMITED
62%
heir period of adjustment. Manufacturing supply service: Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply a…
TRAWSFYNYDD-THERAPEUTICS-INC
TRAWSFYNYDD-THERAPEUTICS-INC
62%
k issued in connection with the reclassification and conversion of redeemable convertible preferred stock $ — $ 111,619,000 Common stock issued in connection with acquisition of Trawsfynydd $…
Traws Pharma, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
TRAW-DEBT-13088
Warrants outstanding: 3057560
90%
xbrl warrant detail from xbrl 2025-12-31.
TRAW-DEBT-13089
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2024-12-31.
Traws Pharma, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Traws Pharma, Inc..
Traws Pharma, Inc. Ownership
Holder
Name
Confidence
Evidence
TRAW-OWNER-ADAGE-CAPITAL-PARTNERS-GP-L-L-C
Adage Capital Partners GP L.L.C.
90%
13F overlay lists Adage Capital Partners GP L.L.C. as top holder; 10 tracked holders.
